Significantly increased quality and lower manufacturing costs for long template mRNAs San Diego, Calif. March 26, 2025 – Primrose Bio, Inc. (“Primrose”), a company developing proprietary therapeutic manufacturing technologies, announces the launch of Prima RNApols™... Primrose Bio, Inc. (“Primrose”), a company with proprietary manufacturing technologies for human therapeutics, and Serum Institute of India Pvt. Ltd. (“SIIPL”), the world’s largest vaccine manufacturer, today announced a collaboration to develop a novel multi-antigen... Primrose Bio, a leading biotechnology company specializing in technologies that improve the manufacturing of next-generation therapeutics, and ExPLoRNA Therapeutics, a pioneering biotechnology company advancing mRNA technologies, vaccines, and therapeutics, announced... Primrose Bio, Inc. (“Primrose,” the “Company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, announced a significant equity investment from 1315 Capital, a... The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has IP and know how in vaccine... Primrose Bio Launches Prima RNApols™ ExTend, an RNA Polymerase for Long-Template mRNA Manufacturing
Primrose Bio to Collaborate with Serum Institute of India to Develop a Novel Multi-Antigen Vaccine
Primrose Bio and ExPLoRNA Therapeutics Announce Strategic Partnership to Advance mRNA Medicines
Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.No Results Found